Inhibikase TherapeuticsIKT
13F holders, Q2 2024 (June 30)At the end of Q2 2024, 12 institutions reported holding Inhibikase Therapeutics Inc. (IKT) in their 13F filings, unchanged from Q1 2024. 4 opened new positions and 4 sold out. The largest holders were Armistice Capital, LLC ($713K), Blair William & Co. ($141K) and Citadel Advisors ($50K). 2 famous investors held it, including Ken Griffin (0.0% of Citadel Advisors's portfolio) and Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio).
- Company
- Inhibikase Therapeutics Inc.
- CUSIP
- 45719W205
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 4 | $764K |
| Exits | 4 | $102K |
All 13F filers, Q1 2024 → Q2 2024: 678,968 shares bought and 48,030 shares sold, net +630,938 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 12 holders
| Armistice Capital, LLC | 0.02% | New | 589,575 | $713K |
| Blair William & Co. | 0.00% | Add +51.6% | 116,120 | $141K |
| Citadel Advisors | 0.00% | New | 37,895 | $50K |
| Geode Capital Management, LLC | 0.00% | Add +30.1% | 37,330 | $49K |
| Renaissance Technologies | 0.00% | Reduce -2.8% | 20,822 | $25K |
| Vanguard Group Inc. | 0.00% | No change | 16,724 | $20K |
| State Street Corp. | 0.00% | No change | 10,084 | $13K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +107.0% | 5,736 | $7K |
| Morgan Stanley | 0.00% | No change | 1,667 | $2K |
| Mather Group, Llc. | 0.00% | New | 334 | $721 |
| Wells Fargo & Company | 0.00% | Reduce -19.3% | 167 | $202 |
| Bank of America Corp. | 0.00% | New | 42 | $51 |
"% of holder's portfolio" is IKT's weight in each manager's 13F, not the share of Inhibikase Therapeutics Inc. the manager owns.